Methotrexate Treatment Could Modulate the Abnormal CD4+T Lymphocyte Subset Distribution in NaÏve Rheumatoid Arthritis Patients

Cristina Bohórquez Heras¹, Lucía Ruiz Gutiérrez¹, Carolina Garcia Torrijos², Ana Turrión Nieves¹, Ana Pérez Gómez¹, Ana Sánchez Atrio¹, Eduardo Cuende¹, Atusa Movasat¹, Fernando Albarrán Hernández¹, Henry Moruno¹, M José León¹, David Diaz², Jorge Monserrat² and Melchor Álvarez de Mon^1,2, ¹University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ²Laboratory of Immune System Diseases, Department of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Arthritis, Lymphocytes and methotrexate (MTX)

Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Mechanisms regulating the chronic autoimmune response in rheumatoid arthritis (RA) are not well understood. However, activated T CD4+ play a pivotal role initiating and perpetuating the chronic inflammation characteristic for the disease. The objetive is evaluate the number and distribution of circulating CD4+ T lymphocytes and their CD4+ naïve T cells (TN), central memory (TCM), non-terminated effector memory (TNTEM) and terminated effector memory (TTEM) T cells subsets in a population of recently diagnosed DMARD naive RA patients before and along the first 6 months of methotrexate (MTX) treatment.

Methods: The number of circulating CD4+ T lymphocytes, and of their TN, TM, TCM and TEM subsets in fifty untreated patients with RA before MTX treatment and at 3 and 6 months of treatment were assayed using a multiparametric flow cytometry. We also studied twenty-four age- and sex-matched healthy subjects as controls.

Results:

RA naïve patients show a significant (p<0.05) expansion of the circulating CD4+ TNTEM subset. MTX non responder naïve RA patients show from basal conditions a significative expansion of CD4+ TNTEM lymphocytes and develop significant expansion of CD4+ TCM, and CD4+ TEM lymphocyte subsets along MTX treatment.

Conclusion: Recently diagnosed DMARD naive RA patients show involvement of the circulating CD4+ T lymphocytes activation/differentiation stage subsets. MTX treatment show immunomodulatory effects on CD4+ T lymphocyte compartment with different behavior in responder and non-responder patients.

Disclosure: C. Bohórquez Heras, None; L. Ruiz Gutiérrez, None; C. Garcia Torrijos, None; A. Turrión Nieves, None; A. Pérez Gómez, None; A. Sánchez Atrio, None; E. Cuende, None; A. Movasat, None; F. Albarrán Hernández, None; H. Moruno, None; M. J. León, None; D. Diaz, None; J. Monserrat, None; M. Álvarez de Mon, None.

To cite this abstract in AMA style:

Bohórquez Heras C, Ruiz Gutiérrez L, Garcia Torrijos C, Turrión Nieves A, Pérez Gómez A, Sánchez Atrio A, Cuende E, Movasat A, Albarrán Hernández F, Moruno H, León MJ, Diaz D, Monserrat J, Álvarez de Mon M. Methotrexate Treatment Could Modulate the Abnormal CD4+T Lymphocyte Subset Distribution in NaÏve Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/methotrexate-treatment-could-modulate-the-abnormal-cd4t-lymphocyte-subset-distribution-in-naive-rheumatoid-arthritis-patients/. Accessed .

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-treatment-could-modulate-the-abnormal-cd4t-lymphocyte-subset-distribution-in-naive-rheumatoid-arthritis-patients/